Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog


Alnylam Pharmaceuticals, Inc. ( ALNY ) inked a collaboration deal with The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, for the continued development of ALN-AAT. ALN-AAT is a subcutaneously administrated ribo nucleic acid interference (RNAi) therapeutic being developed for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease.

TAP works with patients, academia, pharmaceutical and biotech companies and other public health organizations for cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency.

The research and development activities for ALN-AAT will be partially funded by TAP and the rest by Alnylam. The company intends to file an investigational new drug (IND) application for ALN-AAT in mid 2015. Results from pre-clinical studies have shown that treatment with ALN-AAT resulted in approximately 90% knockdown of serum AAT.

As per company sources, there are around 10,000 to 20,000 people in the U.S. and EU respectively suffering from AAT deficiency with associated liver pathology.

Alnylam has made significant progress with its pipeline so far. Patisiran and ALN-TTRsc are two of the most advanced candidates at Alnylam. The company is evaluating patisiran in the phase III APOLLO study in transthyretin-mediated amyloidosis patients suffering from familial amyloidotic polyneuropathy. Alnylam intends to file for regulatory applications for the candidate later in the year.

Meanwhile, ALN-TTRsc is in a phase II study in patients suffering from familial amyloidotic cardiomyopathy. ALN-TTRsc is also an RNAi therapeutic targeting the TTR gene being developed for the treatment of ATTR. The company has multiple pipeline related activities in the coming quarters. We expect investor focus to remain on the development of the pipeline.

Alnylam, a biopharmaceutical company, presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the sector include Regeneron Pharmaceuticals, Inc. ( REGN ), Gilead Sciences Inc. ( GILD ) and Alexion Pharmaceuticals, Inc. ( ALXN ). While Gilead and Regeneron are Zacks Rank #1 (Strong Buy) stocks, Alexion holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ALNYLAM PHARMA (ALNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: TAP , AAT , IND , ALXN , REGN

More from

Related Videos

Spot the Dropout RRC
Spot the Dropout RRC                
Spot the Dropout MG
Spot the Dropout MG                 
Spot the Dropout IPC
Spot the Dropout IPC                



Most Active by Volume

  • $95.21 ▼ 1.84%
  • $18.13 ▼ 0.17%
  • $5.19 ▼ 6.49%
  • $46.88 ▲ 1.27%
  • $3.97 ▲ 0.51%
  • $15.10 ▼ 0.72%
  • $36.08 ▼ 11.61%
  • $122.37 ▼ 0.50%
As of 7/30/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by